Urinary incontinence in gynecological oncology patients

Guiseppe Del Priore, S. Y. Taylor, B. A. Esdaile, R. Masch, Y. Martas, J. Wirth

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The objective of this study was to investigate the prevalence and significance of urinary incontinence (UI) symptoms in gynecological oncology (GO) patients and to test the gynecologists' proficiency in eliciting these symptoms. A prospective survey using questionnaires was designed. Two faculty practice offices in the United States were chosen for the study. Forty GO patients and 40 general gynecology patients were selected from the most recent outpatient appointments of the two hospitals. We used the Urogenital Distress Inventory and the Incontinence Impact Questionnaire to elicit UI symptoms in GO patients and compared the results with their medical records. A control group, selected from a general gynecological practice, was included for comparison. The main outcome measures were to investigate the prevalence and detection rates of UI in GO patients. GO patients were significantly more likely to report UI symptoms on the questionnaire than their gynecologist was able to elicit during a consultation (P <0.001). The survey found that 60% (24/40) of the GO patients reported at least one symptom of UI, with 23% complaining of "severe" symptoms. Of those patients who reported the symptoms on questionnaire, only 5% (2/40) were detected at the initial physician assessment (P <0.01). Eighteen percent of the GO patients reported that the UI symptoms adversely affected their quality of life. The prevalence of symptoms was not associated with the primary cancer site. There was no difference in detection rates between the two practice settings. In a multivariate analysis, there was no factor that emerged as the best discriminator for a positive response to the questionnaire. A significant proportion of GO patients report severe UI symptoms that are not detected by gynecologic oncologists or gynecologists during routine consultations.

Original languageEnglish (US)
Pages (from-to)911-914
Number of pages4
JournalInternational Journal of Gynecological Cancer
Volume15
Issue number5
DOIs
StatePublished - Sep 2005
Externally publishedYes

Fingerprint

Urinary Incontinence
Referral and Consultation
Gynecology
General Practice
Medical Records
Surveys and Questionnaires
Appointments and Schedules
Outpatients
Multivariate Analysis
Quality of Life
Outcome Assessment (Health Care)
Physicians
Equipment and Supplies
Control Groups

Keywords

  • Oncology
  • Urine incontinence

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Cancer Research

Cite this

Del Priore, G., Taylor, S. Y., Esdaile, B. A., Masch, R., Martas, Y., & Wirth, J. (2005). Urinary incontinence in gynecological oncology patients. International Journal of Gynecological Cancer, 15(5), 911-914. https://doi.org/10.1111/j.1525-1438.2005.00153.x

Urinary incontinence in gynecological oncology patients. / Del Priore, Guiseppe; Taylor, S. Y.; Esdaile, B. A.; Masch, R.; Martas, Y.; Wirth, J.

In: International Journal of Gynecological Cancer, Vol. 15, No. 5, 09.2005, p. 911-914.

Research output: Contribution to journalArticle

Del Priore, G, Taylor, SY, Esdaile, BA, Masch, R, Martas, Y & Wirth, J 2005, 'Urinary incontinence in gynecological oncology patients', International Journal of Gynecological Cancer, vol. 15, no. 5, pp. 911-914. https://doi.org/10.1111/j.1525-1438.2005.00153.x
Del Priore, Guiseppe ; Taylor, S. Y. ; Esdaile, B. A. ; Masch, R. ; Martas, Y. ; Wirth, J. / Urinary incontinence in gynecological oncology patients. In: International Journal of Gynecological Cancer. 2005 ; Vol. 15, No. 5. pp. 911-914.
@article{6715fe8d20924e2bac50e2db960cf62b,
title = "Urinary incontinence in gynecological oncology patients",
abstract = "The objective of this study was to investigate the prevalence and significance of urinary incontinence (UI) symptoms in gynecological oncology (GO) patients and to test the gynecologists' proficiency in eliciting these symptoms. A prospective survey using questionnaires was designed. Two faculty practice offices in the United States were chosen for the study. Forty GO patients and 40 general gynecology patients were selected from the most recent outpatient appointments of the two hospitals. We used the Urogenital Distress Inventory and the Incontinence Impact Questionnaire to elicit UI symptoms in GO patients and compared the results with their medical records. A control group, selected from a general gynecological practice, was included for comparison. The main outcome measures were to investigate the prevalence and detection rates of UI in GO patients. GO patients were significantly more likely to report UI symptoms on the questionnaire than their gynecologist was able to elicit during a consultation (P <0.001). The survey found that 60{\%} (24/40) of the GO patients reported at least one symptom of UI, with 23{\%} complaining of {"}severe{"} symptoms. Of those patients who reported the symptoms on questionnaire, only 5{\%} (2/40) were detected at the initial physician assessment (P <0.01). Eighteen percent of the GO patients reported that the UI symptoms adversely affected their quality of life. The prevalence of symptoms was not associated with the primary cancer site. There was no difference in detection rates between the two practice settings. In a multivariate analysis, there was no factor that emerged as the best discriminator for a positive response to the questionnaire. A significant proportion of GO patients report severe UI symptoms that are not detected by gynecologic oncologists or gynecologists during routine consultations.",
keywords = "Oncology, Urine incontinence",
author = "{Del Priore}, Guiseppe and Taylor, {S. Y.} and Esdaile, {B. A.} and R. Masch and Y. Martas and J. Wirth",
year = "2005",
month = "9",
doi = "10.1111/j.1525-1438.2005.00153.x",
language = "English (US)",
volume = "15",
pages = "911--914",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Urinary incontinence in gynecological oncology patients

AU - Del Priore, Guiseppe

AU - Taylor, S. Y.

AU - Esdaile, B. A.

AU - Masch, R.

AU - Martas, Y.

AU - Wirth, J.

PY - 2005/9

Y1 - 2005/9

N2 - The objective of this study was to investigate the prevalence and significance of urinary incontinence (UI) symptoms in gynecological oncology (GO) patients and to test the gynecologists' proficiency in eliciting these symptoms. A prospective survey using questionnaires was designed. Two faculty practice offices in the United States were chosen for the study. Forty GO patients and 40 general gynecology patients were selected from the most recent outpatient appointments of the two hospitals. We used the Urogenital Distress Inventory and the Incontinence Impact Questionnaire to elicit UI symptoms in GO patients and compared the results with their medical records. A control group, selected from a general gynecological practice, was included for comparison. The main outcome measures were to investigate the prevalence and detection rates of UI in GO patients. GO patients were significantly more likely to report UI symptoms on the questionnaire than their gynecologist was able to elicit during a consultation (P <0.001). The survey found that 60% (24/40) of the GO patients reported at least one symptom of UI, with 23% complaining of "severe" symptoms. Of those patients who reported the symptoms on questionnaire, only 5% (2/40) were detected at the initial physician assessment (P <0.01). Eighteen percent of the GO patients reported that the UI symptoms adversely affected their quality of life. The prevalence of symptoms was not associated with the primary cancer site. There was no difference in detection rates between the two practice settings. In a multivariate analysis, there was no factor that emerged as the best discriminator for a positive response to the questionnaire. A significant proportion of GO patients report severe UI symptoms that are not detected by gynecologic oncologists or gynecologists during routine consultations.

AB - The objective of this study was to investigate the prevalence and significance of urinary incontinence (UI) symptoms in gynecological oncology (GO) patients and to test the gynecologists' proficiency in eliciting these symptoms. A prospective survey using questionnaires was designed. Two faculty practice offices in the United States were chosen for the study. Forty GO patients and 40 general gynecology patients were selected from the most recent outpatient appointments of the two hospitals. We used the Urogenital Distress Inventory and the Incontinence Impact Questionnaire to elicit UI symptoms in GO patients and compared the results with their medical records. A control group, selected from a general gynecological practice, was included for comparison. The main outcome measures were to investigate the prevalence and detection rates of UI in GO patients. GO patients were significantly more likely to report UI symptoms on the questionnaire than their gynecologist was able to elicit during a consultation (P <0.001). The survey found that 60% (24/40) of the GO patients reported at least one symptom of UI, with 23% complaining of "severe" symptoms. Of those patients who reported the symptoms on questionnaire, only 5% (2/40) were detected at the initial physician assessment (P <0.01). Eighteen percent of the GO patients reported that the UI symptoms adversely affected their quality of life. The prevalence of symptoms was not associated with the primary cancer site. There was no difference in detection rates between the two practice settings. In a multivariate analysis, there was no factor that emerged as the best discriminator for a positive response to the questionnaire. A significant proportion of GO patients report severe UI symptoms that are not detected by gynecologic oncologists or gynecologists during routine consultations.

KW - Oncology

KW - Urine incontinence

UR - http://www.scopus.com/inward/record.url?scp=28944452925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28944452925&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2005.00153.x

DO - 10.1111/j.1525-1438.2005.00153.x

M3 - Article

C2 - 16174244

AN - SCOPUS:28944452925

VL - 15

SP - 911

EP - 914

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 5

ER -